Skip header and navigation

3 records – page 1 of 1.

[20-year results of the research at the adolescent department of the Central Research Institute of Tuberculosis].

https://arctichealth.org/en/permalink/ahliterature194815
Source
Probl Tuberk. 2001;(1):55-8
Publication Type
Article
Date
2001

[Primary drug resistance of Mycobacterium tuberculosis in adolescents with tuberculosis: the specific features of its clinical course, the efficiency of treatment].

https://arctichealth.org/en/permalink/ahliterature155610
Source
Probl Tuberk Bolezn Legk. 2008;(5):17-20
Publication Type
Article
Date
2008
Author
V A Firsova
F G Poluektova
A P Ryzhova
Source
Probl Tuberk Bolezn Legk. 2008;(5):17-20
Date
2008
Language
Russian
Publication Type
Article
Keywords
Adolescent
Adult
Antitubercular Agents - therapeutic use
Female
Humans
Incidence
Laser Therapy - methods
Male
Physical Therapy Modalities
Retrospective Studies
Russia - epidemiology
Severity of Illness Index
Tuberculosis, Multidrug-Resistant - diagnosis - epidemiology - therapy
Abstract
Ninety adolescents suffering from tuberculosis with primary drug resistance (PDR) in Mycobacterium tuberculosis (MBT) were followed up. All the patients had active, marked processes, mainly infiltrative tuberculosis in the phase of decay and dissemination. MBT resistance to 3 drugs or more was detected in most patients (62.3%). Multidrug resistance was 32.2%. The course of the disease was chiefly favorable. An exacerbation of the process occurred during therapy in 6.6% of patients. In patients with PDR, abacillation occurred in 100% of cases and the decay cavities closed in 86.6% by the end of the course of therapy. The PDR patients received treatment with both first- and second-line drugs, had surgery, collapsotherapy, laser therapy, and physiotherapeutic treatments, and lidase. Treatment of patients with drug-resistant tuberculosis presents severe difficulties. However, good results can be achieved in most patients, by applying an individual approach to each patient and determining the optimum chemotherapy regimens and pathogenetic treatments.
PubMed ID
18711813 View in PubMed
Less detail